NEUREN PHARMACEUTICALS LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.47 AUD | +0.41% |
|
-10.03% | -22.03% |
| 05-28 | Transcript : Neuren Pharmaceuticals Limited - Shareholder/Analyst Call | |
| 05-27 | Neuren Phase 2 Trial Shows Significant Improvements in Pitt Hopkins Syndrome | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| NEUREN PHARMACEUTICALS LIMITED | Other Pharmaceuticals | +0.41% | -10.03% | -22.03% | +51.05% | +1,550.00% | 1.64B |  | |  |
Technical Rankings Surperformance
- Stock Market
- Equities
- NEU Stock
- Charts Neuren Pharmaceuticals Limited
- Comparison Chart
